TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03579121

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacogenomic (PGx)
Description: Administer a pharmacogenomics test (buccal swab) during the pre-operative setting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic (PGx)
Description: Administer a pharmacogenomics test (buccal swab) during the pre-operative setting
Study: NCT02675257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interventions to increase diabetes treatment motivation
Description: Interventions to increase diabetes treatment motivation in order to achieve improvements of glycaemic control as well as recovery from affective problems

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activation of personal and social resources
Description: Activation of personal and social resources with a view to diabetes control and affective problems
Study: NCT03579121

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Review results
Description: Pharmacogenomic (PGx) results reviewed by the clinicians during their treatment and the results may guide clinical decisions.
Study: NCT02204436

Intervention type: OTHER
Group type: OTHER
Intervention: Emulsion and gel
Description: A fixed similar quantity of both emulsion and gel were applied consequentially on the hand twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage, until complete absorption, for 8 weeks.
Study: NCT00741598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine-ER
Description: Galantamine-ER 8 to 24 mg per day for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Galantamine placebo
Description: Galantamine placebo 8 to 24 mg per day for 16 weeks
Study: NCT02742025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inclusion visit
Description: This visit takes place between days -15 and -7 preceding a coronarography scheduled for Day 0. It is part of standard care and corresponds to a required cardiology consultation.

Intervention type: OTHER
Group type: OTHER
Intervention: Inclusion visit
Description: This visit takes place between days -15 and -7 preceding a coronarography scheduled for Day 0. It is part of standard care and corresponds to a required cardiology consultation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse consultation
Description: This visit takes place on the same day as the inclusion visit and includes practical advice concerning the hospital stay, explanations concerning the surgical act and practical advice on its implementation, information on the length of stay and after. An explanatory booklet concerning the surgical procedure is provided to the patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone contact
Description: A nurse will telephone the patient 72h to 48h before the coronarography scheduled for day 0. During the telephone conversation the nurse will assess the patient's knowledge about his/her pathology, his/her examination and the course of hospitalization. The nurse will answer any questions and if needed provide further information.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronarography on day 0
Description: This coronarography is scheduled as part of the patient's routine care. This is not an experimental intervention under evaluation.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronarography on day 0
Description: This coronarography is scheduled as part of the patient's routine care. This is not an experimental intervention under evaluation.
Study: NCT02959905

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TSA-CTL
Description: Patients will receive TSA-CTL iv over 20-30 minutes on day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TSA-CTL
Description: Patients will receive TSA-CTL iv over 20-30 minutes on day 0.
Study: NCT03974529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive running
Description: The patients who are assigned to this group will be required to finish a 90 minutes of training protocol, containing 30 minutes' warm-up stretching, and 60 minutes of supervised progressive aerobic endurance track running. The training takes place two time per week, for 24 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: The patients who are assigned to this group will be required to finish a 60 minutes of physiotherapy session. The training takes place once per week, for 24 weeks.
Study: NCT04274075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-9545 Tablet, Fasted: Treatment A
Description: One dose of the GDC-9545 Phase 1 reference tablet formulation (three 10-mg tablets) administered orally with approximately 240 mL room temperature water after at least an 8-hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-9545 Tablet, Fasted: Treatment A
Description: One dose of the GDC-9545 Phase 1 reference tablet formulation (three 10-mg tablets) administered orally with approximately 240 mL room temperature water after at least an 8-hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-9545 Tablet, Fasted: Treatment A
Description: One dose of the GDC-9545 Phase 1 reference tablet formulation (three 10-mg tablets) administered orally with approximately 240 mL room temperature water after at least an 8-hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-9545 Tablet, Fasted: Treatment A
Description: One dose of the GDC-9545 Phase 1 reference tablet formulation (three 10-mg tablets) administered orally with approximately 240 mL room temperature water after at least an 8-hour fast.
Study: NCT02675257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduction of barriers to self-care/glycaemic control
Description: Definition and reduction of barriers to adequate diabetes self-care behaviour as well as good glycaemic control

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring of diabetes-related problems
Description: Cognitive restructuring of diabetes-related problems such as suboptimal glycaemic control and diabetes-related affective problems

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal definition regarding self-care/glycaemia/well-being
Description: Goal definition and agreement regarding diabetes self-care behaviour, optimal glycaemic control and activities supporting well-being and recovery from affective symptoms

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health care and specific topics (e. g. blood pressure)
Description: Education on health care and specific topics (e. g. blood pressure)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy foods, cooking recommendations, recipes
Description: Education on healthy and unhealthy foods, cooking and recipes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sports, activities and exercise
Description: Education on sports, activities and exercise
Study: NCT02959905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 500 mg/m2/day iv on day -5 for one day.
Study: NCT02675257

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Foot care: exercises, care & control, injuries, neuropathy
Description: Education on foot care: exercises, care and control, injuries, and diabetic neuropathy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes complications
Description: Education on diabetes complications

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social aspects of living with diabetes
Description: Education on social aspects of living with diabetes
Study: NCT03748862

Intervention type: OTHER
Intervention: Taper Plan
Description: Occurrence of a taper plan defined by a primary care provider during the follow-up period. Evidence of a taper plan will be obtained by searching prescriptions (SIGs) and medical encounter notes using natural language processing (NLP).

Intervention type: OTHER
Intervention: Taper Plan
Description: Occurrence of a taper plan defined by a primary care provider during the follow-up period. Evidence of a taper plan will be obtained by searching prescriptions (SIGs) and medical encounter notes using natural language processing (NLP).
Study: NCT02261077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide
Study: NCT02959905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2/day iv over 30 minutes on day -5 and -4 for two days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2/day iv over 30 minutes on day -5 and -4 for two days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 500 mg/m2/day iv on day -5 and -4 for two days.
Study: NCT03821220

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interview support and Dietitian support
Description: Three sessions of a structured motivational support intervention. Each patient will be required to set a SMART physical activity personal objective. The sessions will cover possible barriers and facilitators, enhancing self-efficacy, and feedback. In addition two sessions with a dietitian to discuss ways to improve current health habits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activity tracker plus usual care
Description: Each patient will receive their own activity tracker (vivofit 3) with instructions on use, in addition to usual care, and written handouts for pre-diabetic patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activity tracker plus usual care
Description: Each patient will receive their own activity tracker (vivofit 3) with instructions on use, in addition to usual care, and written handouts for pre-diabetic patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activity tracker plus usual care
Description: Each patient will receive their own activity tracker (vivofit 3) with instructions on use, in addition to usual care, and written handouts for pre-diabetic patients.
Study: NCT02261077

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02443753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoBarrier SANS
Description: Eligible subjects will be implanted with the EndoBarrier® SANS™ Device for a period of 3 months. The GI Dynamics' EndoBarrier® SANS™ is an endoscopically positioned device that represents an alternative to the use of gastric bypass operative techniques as a means of re-routing food and altering the gut-hormone axis. The EndoBarrier® SANS™ provides an alternate passage of chime through the duodenum and proximal sixty centimeters of jejunum replicating in part the bypass of bariatric surgery.
Study: NCT02171299

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wound infiltration with local anaesthetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study: NCT04223544

Intervention type: DIAGNOSTIC_TEST
Intervention: Influenza POC and laboratory testing
Description: Participation in the study is voluntary and carried out after the consent of the examined person. The examination consists of: 1) completing the questionnaire and 2) taking the throat swab twice by the researcher. Two throat swab samples will be taken at the same time. Both samples will be used for virological examination to determine the presence of influenza virus material using non-invasive tests: one sample will be analyzed by a quick 'on-site' test - Flu SensDx kit, while the other sample will be transported to the laboratory, where the reverse transcriptase polymerase chain reaction (RT-PCR) - reference method - will be performed to confirm the presence of influenza genetic material. Swabs are planned to be collected during the 2019/2020 influenza epidemic season (January-March).

Intervention type: DIAGNOSTIC_TEST
Intervention: Influenza POC and laboratory testing
Description: Participation in the study is voluntary and carried out after the consent of the examined person. The examination consists of: 1) completing the questionnaire and 2) taking the throat swab twice by the researcher. Two throat swab samples will be taken at the same time. Both samples will be used for virological examination to determine the presence of influenza virus material using non-invasive tests: one sample will be analyzed by a quick 'on-site' test - Flu SensDx kit, while the other sample will be transported to the laboratory, where the reverse transcriptase polymerase chain reaction (RT-PCR) - reference method - will be performed to confirm the presence of influenza genetic material. Swabs are planned to be collected during the 2019/2020 influenza epidemic season (January-March).
Study: NCT05614622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclopentolate Hydrochloride 1.0% eye drops
Description: A short-acting mydriatic agent
Study: NCT00951470

Intervention type: OTHER
Group type: OTHER
Intervention: Follow -Up Visits
Description: If CDT is declined, participants will have follow-up visits at 1, 3, and 6 months after study interview.

Intervention type: OTHER
Group type: OTHER
Intervention: Full CDT
Description: Monday through Friday visits to the clinic for 2 weeks of intensive outpatient therapy. The CDT will be done by the lymphedema therapist. Each session will last about 1 hour.~During the last 2 treatment visits (Visits 9 and 10), the participant will be taught how to do the CDT steps at home. Then, the CDT steps will be performed at home, every day for the next 3 months.

Intervention type: OTHER
Group type: OTHER
Intervention: Modified CDT Program
Description: The participant will come to the clinic for 1-2 training sessions taught by the lymphedema therapist. Each training session will last about 1 hour, and the participant will be taught how to do the CDT steps at home. Then, the CDT steps will be performed at home, every day for the next 3 months.
Study: NCT02900950

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multicolour inking specimens

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Monocolour inking specimens
Study: NCT04456387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
Description: Participants received on-demand treatment, doses range from 30 IU/kg to 50 IU/kg, or doses divided on the discretion of the Investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
Description: Participants received prophylaxis treatment at 50 IU/kg every three days.
Study: NCT01083953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Comparing the optimal end-tidal concentration sevoflurane and desflurane for LMA extubation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Comparing the optimal end-tidal concentration sevoflurane and desflurane for LMA extubation
Study: NCT02646020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: aprepitant 125mg d1, 80mg d3 and d5; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine
Description: Desloratadine 5mg d1-d28; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of aprepitant
Description: Placebo of aprepitant 125mg d1, 80mg d3 and d5; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of desloratadine
Description: Placebo of desloratadine 5mg d1-d28; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
Study: NCT04538846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culinary art therapy
Description: Culinary art therapy is a novel approach which broadly perceives food and cooking as enabling participants to explore needs, patterns and relationships and facilitate therapeutic processes.
Study: NCT02872558

Intervention type: OTHER
Group type: OTHER
Intervention: Acute Otitis Media Choice Decision Aid
Description: Decision Aid

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual Care
Study: NCT02357602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-7340
Description: Medication is supplied in 10 or 25mg tablets, so subjects will receive either 1/2 or one tablet in a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-7340
Description: Medication is supplied in 10 or 25mg tablets, so subjects will receive either 1/2 or one tablet in a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-7340
Description: Medication is supplied in 10 or 25mg tablets, so subjects will receive either 1/2 or one tablet in a single dose.
Study: NCT02160730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-roscovitine
Description: See Arm Description
Study: NCT03248544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: Fat-soluble vitamin D injection contain of 300,000 IU vitamin D that given via intramuscular injection

Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: No intervention
Study: NCT02323958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupoint stimulation
Description: stimulation is given at acupoints

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: non-acupoint stimulation
Description: stimulation is given at acupoints

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrode attached
Description: electrodes are attached to skin

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: electrode attached
Description: electrodes are attached to skin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: electrode attached
Description: electrodes are attached to skin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical stimulation
Description: electrical stimulation is given through electrodes attached to th skin

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: electrical stimulation
Description: electrical stimulation is given through electrodes attached to th skin
Study: NCT05288829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1210 SC
Description: All doses of ALXN1210 SC were administered by four 100-milligram (mg) SC injections of 1 milliliter (mL) each in the abdominal area. All four 1-mL injections were administered over a 15-minute period with at least 15 minutes between the end of injection in 1 participant and the start of injection in the next participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1210 IV
Description: All doses of ALXN1210 IV were administered by IV infusion, using IV sets with in-line filters, at a maximum rate of 333 mL/hour, excluding interruption for safety or technical reason. There were at least 15 minutes between the end-of-infusion/injection in 1 participant and the start-of infusion/injection in the next participant.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All doses of placebo SC were administered by four 100-mg SC injections of 1 mL each in the abdominal area. All four 1-mL injections were administered over a 15-minute period with at least 15 minutes between the end of injection in 1 participant and the start of injection in the next participant.
Study: NCT04389034

Intervention type: DRUG
Intervention: Pollinex Quattro with tree- and grass pollen extracts and their mixtures
Description: retrospective analysis of patient records of allergen-specific immunotherapy
Study: NCT02699827

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine hydrochloride
Description: Patients will receive epidural 20 ml levobupivacaine hydrochloride 0.5%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levobupivacaine hydrochloride
Description: Patients will receive epidural 20 ml levobupivacaine hydrochloride 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate
Description: Patients will receive epidural 5 ml magnesium sulphate 10%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: Patients will receive epidural 5 ml saline 0.9%
Study: NCT04264754

Intervention type: PROCEDURE
Intervention: Blood collection
Description: Peripheral blood will be collected via routine venipuncture procedure

Intervention type: PROCEDURE
Intervention: Blood collection
Description: Peripheral blood will be collected via routine venipuncture procedure
Study: NCT01238419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physiotulle
Description: Physiotulle is a non adherent dressing, composed of a polyester fabric impregnated with hydrocolloid particles (CMC) suspended in vaseline

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: URGOTUL
Description: Urgotul is an non occlusive dressing comprising of a polyester mesh impregnated with hydrocolloid particles dispersed on a petroleum jelly matrix
Study: NCT03776526

Intervention type: BEHAVIORAL
Intervention: Fitbit® Alta HR Sleep monitoring
Description: Patients will be fitted with a Fitbit® Alta HR after surgery, which will monitor sleep quality (sleep duration and number of awakenings) for the duration of hospitalization.
Study: NCT04414423

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow concentrate alveolar cleft grafting
Description: patients will undergo surgery to repair alveolar cleft with autogenous bone graft combined with bone marrow concentrate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous alveolar grafting
Description: patients will undergo surgery to repair alveolar cleft with autogenous bone graft
Study: NCT02169297

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Sub-Paraspinal Block
Description: Treatment group received bilateral ultrasound-guided placement of multi-perforated soaker catheter at sub-paraspinal location. Catheter position was considered adequate when live ultrasound imaging confirmed placement directly over the rib surface and lateral to the transverse process at the T2-T10 level. An infusion of ropivacaine 0.2% was started via the On-Q infusion system at a rate of 0.25 mg/kg/hour per catheter (maximum of 8 ml/hr catheter \[maximum pump infusion rate\]). The local anesthetic infusion was stopped on post-operative day number 3 and the catheters removed.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PCA only
Description: Patients received intravenous PCA post-operatively

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCA only
Description: Patients received intravenous PCA post-operatively